Editor’s Note: This is part three of a three-part Healio Exclusive series on the development and use of AI to improve clinical outcomes in cardiovascular medicine and considerations for regulatory labeling and patient privacy . Part 1 can be viewed here. Part 2 can be viewed here.
Request permissions for this article. Beijing Anzhen Hospital, the Capital Medical University, Beijing, China Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institutes of Biomedical…
The evolving landscape of musculoskeletal interventional oncology treatment for the management of painful bone metastases.
SAN ANTONIO — A swallowable hydrogel capsule that expands in the stomach demonstrated significant weight-loss, cardiovascular, glycemic and quality of life benefits for patients with…
PHILADELPHIA — Rebyota was safe and effective at 8 weeks and up to 6 months in patients with recurrent Clostridioides difficile infection, many of whom…
AI-supported mammography screening resulted in a similar cancer detection rate compared with standard double reading, with a substantially lower screen-reading workload, indicating that the use…
Johnson & Johnson is now the third company with an FDA-approved PFA system in its portfolio, joining Medtronic and Boston Scientific. Varipulse previously gained CE…
The ISHLT Annual Meeting is multidisciplinary, international, and one of the largest gatherings focused on treating advanced heart and lung disease.
Cardiovascular diseases are the leading cause of death among women, and the incidence among younger women has shown the greatest increase over the last decades,…
